vimarsana.com
Home
Live Updates
GenSight Biologics S.A.: GenSight Biologics to Host Key Opin
GenSight Biologics S.A.: GenSight Biologics to Host Key Opin
GenSight Biologics S.A.: GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ in the US
December 2, 2021, at 8:00 am EST 2:00 pm CET Connection details for live call and translation provided Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME
Related Keywords
Louisiana ,
United States ,
New Orleans ,
Paris ,
France General ,
France ,
French ,
American ,
James Palmer ,
Gensight Biologics Euronext ,
Seanp Donahue ,
Gensight Biologics ,
Thomas Gidoin ,
Guillaume Van Renterghem ,
Jeanene Timberlake ,
Clinical Affairs ,
European Union ,
European Medicines Agency ,
Vanderbilt University ,
Meeting Of The American Academy Ophthalmology ,
Sight Biologics ,
Leber Hereditary Optic Neuropathy ,
American Academy ,
Coleman Professor ,
Vice Chair ,
Pediatric Ophthalmology Department ,
Vanderbilt Children ,
Sight Biologic ,
Mitochondrial Targeting Sequence ,
Gensight Biologic ,
Hereditary Optic Neuropathy ,
Institut De La Vision ,
Adeno Associated Virus ,
Financial Officer ,
Gensight ,
Iologics ,
Most ,
Opinion ,
Leader ,
Ebcast ,
Outcomes ,
Mong ,
Compassionate ,
Patients ,
Reated ,
Unilaterally ,
Umevoq ,